Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest SSM-N-8 Regulus Stories

2014-01-07 16:25:27

LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 8:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA....

2013-12-23 08:26:30

LA JOLLA, Calif., Dec. 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has been selected for addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 23, 2013. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock MarketĀ® that...

2013-11-13 16:26:39

- Regulatory Application for RG-101 to be Filed in the Near Term: Clinical Studies in Man Expected to Commence in Early 2014 - LA JOLLA, Calif., Nov. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2013 and provided a summary of recent corporate highlights. "This was a remarkably productive third...

2013-11-06 16:31:04

LA JOLLA, Calif., Nov. 6, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended September 30, 2013 on Wednesday, November 13, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Wednesday, November 13, 2013 at 5:00 pm Eastern...

2013-08-13 16:26:17

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End - LA JOLLA, Calif., Aug. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended June 30, 2013 and provided a summary of recent corporate highlights. "The second...

2013-08-06 16:28:39

LA JOLLA, Calif., Aug. 6, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2013 on Tuesday, August 13, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, August 13, 2013 at 5:00 pm Eastern Daylight Time to...

2013-07-23 08:30:40

LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the completion of an underwritten public offering of 5,175,000 shares of common stock, including 675,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a price to the public of $9.50 per...

2013-06-11 08:30:59

LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors effective immediately. Dr. Papadopoulos assumes the role of Chairman of the Board from John Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who has been...

2013-05-21 16:27:26

LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT. The conference is being held at the Westin Boston...

2013-05-07 16:29:08

LA JOLLA, Calif., May 7, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2013 on Tuesday, May 14, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, May 14, 2013 at 5:00 pm Eastern Daylight Time to discuss its...